Latest News

November 16, 2022 12pm NZDT AUCKLAND, New Zealand — Pictor, a global leader in immunodiagnostics, today announced that its PictArray™ SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test will soon be available in New Zealand. Rako Science will utilize its national network by collecting blood samples with a device from Tasso, Inc., and undertake testing […]

Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis (MAP) – also known as Johne’s disease, that could save the New Zealand dairy industry upwards of $80 million a year in lost production. “The PictArray™ MAP assay would be a positive addition to national control programs to help in the eradication of Johne’s disease from the dairy industry,” says Pictor’s Director of Research and Development, Dr. Natasha Gordon, who will be presenting at a Johne’s disease conference this week in Dublin, Ireland.

Following a new investment of $6.1 million (NZD $8.8 million), biotech company Pictor today announced a partnership with U.S. laboratory service provider Mobility Health, launching a new antibody test as an important advance in COVID-19 monitoring and treatment. The investment, led by former Morrison & Co CEO Marko Bogoievski, and specialist growth investor K One W One Ltd. (K1W1), will support market and product development of the new antibody test and other Pictor in vitro diagnostics.

New Zealand diagnostic biotech company Pictor Ltd. announced today that it has successfully completed validation trials at two separate sites in the United States, one of which was Florida-based Boca Biolistics, for its COVID-19 antibody test. “We were delighted with the performance observed in the Alpha studies which gave us confidence to rapidly proceed with trials in the USA,” said Pictor Chief Technology Officer Dr. Richard Janeczko. “We feel the duplex nature of our test is a unique feature which provides much better data interpretation from serology testing for use the ongoing management of the global pandemic.” The company now aims to fast-track adoption of its low-cost, high-performance, high-throughput tests by obtaining FDA Emergency Use Authorization.